Hydroxyclo-zinc is a drug that was approved for treating a rare form of cancer called B-cell lymphoma.
But its use is controversial because of concerns that it can be used for more than one kind of cancer.
It has been used to treat patients with advanced prostate cancer, but some researchers are concerned it can cause serious side effects and lead to unnecessary hospitalization.
The drug is approved for the treatment of acute lymphoblastic leukemia (ALL), but is also being studied for the rare and potentially fatal non-ALL form of the disease.
A study published in the journal Scientific Reports found that the drug is associated with serious adverse reactions.
According to the report, the drugs main mechanism of action was via an interaction with a protein called T-helper 1 (Th1), a protein that can trigger an immune response that leads to a reduction in the production of the cancer-causing tumor suppressor CD8+ T-cells.
This reduces the ability of the immune system to fight the disease and could lead to cancer recurrence.
The study also found that patients taking the drug had an increased risk of bleeding, increased levels of antibodies, and elevated liver enzymes, suggesting the drug could have serious side-effects.
The Canadian drugmaker, Candelario Inc., says the drug has never been used for this type of cancer and that it has been removed from the market.
However, the company’s CEO, John Fadley, says the company has been monitoring the study for more then a year, but he did not release a specific date for when it was done.
“There is a concern that if we did that, we would be removing this drug,” he told the CBC.
Fadler says the research is ongoing and that there is a process that Candelaria has to go through to have the drug removed from its shelves.
However it has not said whether it will remove the drug from its market, nor will it release any further information about the study.
The company has also released a statement to CBC News saying it is “monitoring the situation” and will “make a final decision” when it is done.
Fadaley said that Candela is “extremely cautious” about what it does with its data and says the firm is taking the data very seriously.
“This is a very serious problem and we have had some people in the company for over two years that have had serious health issues,” he said.
“So, we are very careful about what we do with that data.
We are not taking anything for granted and we will be following the proper protocols to do that.”
The Canadian government has announced that it will ban the use of Hydroxy Clo- Zinc in ALL patients and will also ban its use in B-cells (the cells that carry the cancer).
In an email sent to CBC on Thursday, Health Minister Peter MacKay said the government’s position is that the use or distribution of the drug for any other reason will result in criminal charges.
The ban is part of a broader plan to curb the use and distribution of prescription drugs in the province, which has seen a surge in infections due to a spike in drug-resistant infections and the death of several people from the disease, including two children.
In January, Health Canada announced that the province would ban the sale of Hydrocycloza, a generic version of Hydrocloze.
The news came after a report from the Institute for Safe Medicines said the drug’s approval in Canada had not been renewed due to concerns about safety and efficacy.
The Institute for Safety and Responsible Drug Use in Medicine and Public Health (ISEPSH) said that there were concerns about the safety of the drugs ability to reduce B-Cell-Lymphoma (B-LL) and that its use should be restricted to those who have advanced liver disease.
The report said there were also concerns about other drugs being used to enhance their effectiveness.
According the report from ISEP, there are no approved medications for B-LL or B-CL.
The ISEP report said Hydrocycles approval in other countries was revoked because it was found to be a risk to patients with liver disease and other organ systems.
“The use of these drugs to treat other diseases is also illegal in Canada,” the report said.
Candelarie Inc. issued a statement on Thursday saying it had not received any government order to stop its sales.
“Candela is a safe, effective and efficacious drug and we do not intend to alter its use, manufacture, marketing or distribution as a result of these reports,” the company said in a statement.
However Candela, which is a subsidiary of Candelaro Inc., told CBC News that it was not aware of any order to suspend its sales and was not prepared to comment further.
The drugs company said it has had a number of adverse reactions from its products in the past